{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2.9","upperLimit":"16.4","value":"11.5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"10"}],"units":"Participants"}],"description":"Analysis will be performed using Kaplan-Meier estimates. Time from date on treatment to date of progression for patients who progressed or date of death for patients who died without progressing. The observations of patients remaining alive and progression free were censored at date of last disease evaluation.","dispersionType":"95% Confidence Interval","groups":[{"description":"TREATMENT PHASE (COURSES 1-8): Patients receive carfilzomib IV over 30 minutes on days 1, 2, 8, 9, 15, and 16. Treatment repeats every 28 days for 8 courses in the absence of disease progression or unacceptable toxicity. Patients achieving less than PR also receive dexamethasone PO or IV weekly in courses 4-8.\n\nMAINTENANCE PHASE (COURSES 9-14): Patients receive carfilzomib IV over 30 minutes on days 1, 2, 15, and 16. Patients who received dexamethasone in the Treatment Phase continue to receive dexamethasone PO or IV weekly. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity.\n\ncarfilzomib: Given IV\n\ndexamethasone: Given IV or PO\n\nlaboratory biomarker analysis: Correlative studies","id":"OG000","title":"Treatment (Carfilzomib, Dexamethasone)"}],"paramType":"MEDIAN","populationDescription":"All patients enrolled and received treatment.","reportingStatus":"POSTED","timeFrame":"Time from first dose to first observed disease progression or death, assessed up to 2 years","title":"Progression-free Survival (PFS)","type":"SECONDARY","unitOfMeasure":"months"}